Synermore Biologics Co., Ltd.
Quick facts
Marketed products
Phase 3 pipeline
- SYN023 · Oncology
SYN023 is a monoclonal antibody targeting the PD-1 receptor.
Phase 1 pipeline
- Adalimumab European source · Immunology
Tumour necrosis factor-alpha inhibitor - Adalimumab North American source
- SYN004
- SYN060
- SYN125
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: